Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0020676
Disease: Hypothyroidism
Hypothyroidism 		0.010 Biomarker disease BEFREE Low T4 was observed in preterm infants irrespective of the cause of preterm birth, while maternal (TSH) and placental (DiO2, DiO3, and MCT10) compensatory responses were only activated in indicated preterm birth due to vascular complications. 29557697 2019
CUI: C0013170
Disease: Drug habituation
Drug habituation 		0.010 Biomarker phenotype BEFREE Tat1-86 induced developmental neurotoxic effects, as witnessed by delays in eye opening, delays in early reflex development and alterations in prepulse inhibition (PPI) and between-session habituation of locomotor activity. 25285887 2014
CUI: C0024301
Disease: Lymphoma, Follicular
Lymphoma, Follicular 		0.010 Biomarker disease BEFREE A spontaneously EBV transformed follicular lymphoma (FL) cell line, Tat-1, was established from the lymph node biopsy specimen of a patient with B cell FL, grade 1 in transformation to high grade disease. 11840295 2002
CUI: C3854222
Disease: Human immunodeficiency virus (HIV) II infection category B1
Human immunodeficiency virus (HIV) II infection category B1 		0.010 GeneticVariation disease BEFREE Activity of human immunodeficiency virus type 1 promoter/TAR regions and tat1 genes derived from individuals with different rates of disease progression. 9191845 1997
CUI: C0279680
Disease: Transitional cell carcinoma of bladder
Transitional cell carcinoma of bladder 		0.010 Biomarker disease BEFREE Association of PAX5 expression with clinical outcome in patients with TaT1 transitional cell carcinoma of the bladder. 16566978 2006
CUI: C0036690
Disease: Septicemia
Septicemia 		0.010 AlteredExpression disease BEFREE CLP induced sepsis resulted in reduced: (1) T<sub>4</sub> serum levels; (2) <i>Dio1, Slc16a2, Slc16a10, Thra</i>, and <i>Thrb</i> expression in liver as well as <i>Slc16a2</i> expression in the thyroid gland (3) <i>Thrb</i> and <i>Tshb</i> mRNA expression in the pituitary; (4) total leukocyte counts in the bone marrow while increased its number in peritoneal and pleural fluids. 29118715 2017
CUI: C0243026
Disease: Sepsis
Sepsis 		0.010 AlteredExpression disease BEFREE CLP induced sepsis resulted in reduced: (1) T<sub>4</sub> serum levels; (2) <i>Dio1, Slc16a2, Slc16a10, Thra</i>, and <i>Thrb</i> expression in liver as well as <i>Slc16a2</i> expression in the thyroid gland (3) <i>Thrb</i> and <i>Tshb</i> mRNA expression in the pituitary; (4) total leukocyte counts in the bone marrow while increased its number in peritoneal and pleural fluids. 29118715 2017
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms 		0.010 Biomarker group BEFREE DNA cytometric features in biopsies of TaT1 urothelial cell cancer predict recurrence and stage progression more accurately than stage, grade, or treatment modality. 12809927 2003
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.010 Biomarker group BEFREE DNA cytometric features in biopsies of TaT1 urothelial cell cancer predict recurrence and stage progression more accurately than stage, grade, or treatment modality. 12809927 2003
CUI: C1827293
Disease: Carcinoma of urinary bladder, invasive
Carcinoma of urinary bladder, invasive 		0.010 GeneticVariation disease BEFREE European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update. 31443960 2019
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.020 AlteredExpression group BEFREE Expression of tumor-associated trypsinogens (TAT-1 and TAT-2) in prostate cancer. 15651064 2005
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate 		0.010 Biomarker disease BEFREE Expression of tumor-associated trypsinogens (TAT-1 and TAT-2) in prostate cancer. 15651064 2005
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma 		0.010 Biomarker disease BEFREE Expression of tumor-associated trypsinogens (TAT-1 and TAT-2) in prostate cancer. 15651064 2005
CUI: C0005684
Disease: Malignant neoplasm of urinary bladder
Malignant neoplasm of urinary bladder 		0.010 AlteredExpression disease BEFREE Focusing on patients with TaT1 non-muscle invasive BCa, BCL2L12 expression levels were correlated with higher recurrence rate at the first follow-up cystoscopy and were unveiled to be an independent unfavorable predictor of patients' short-term recurrence following transurethral resection. 23790536 2014
CUI: C0005695
Disease: Bladder Neoplasm
Bladder Neoplasm 		0.010 AlteredExpression disease BEFREE Focusing on patients with TaT1 non-muscle invasive BCa, BCL2L12 expression levels were correlated with higher recurrence rate at the first follow-up cystoscopy and were unveiled to be an independent unfavorable predictor of patients' short-term recurrence following transurethral resection. 23790536 2014
CUI: C0699885
Disease: Carcinoma of bladder
Carcinoma of bladder 		0.010 AlteredExpression disease BEFREE Focusing on patients with TaT1 non-muscle invasive BCa, BCL2L12 expression levels were correlated with higher recurrence rate at the first follow-up cystoscopy and were unveiled to be an independent unfavorable predictor of patients' short-term recurrence following transurethral resection. 23790536 2014
CUI: C0003872
Disease: Arthritis, Psoriatic
Arthritis, Psoriatic 		0.100 GeneticVariation disease GWASCAT Genetic variation at the glycosaminoglycan metabolism pathway contributes to the risk of psoriatic arthritis but not psoriasis. 30552173 2019
CUI: C0523465
Disease: Serum albumin measurement
Serum albumin measurement 		0.100 GeneticVariation phenotype GWASDB Genome-wide association study identifies multiple loci influencing human serum metabolite levels. 22286219 2012
CUI: C0201874
Disease: Amino acids measurement
Amino acids measurement 		0.100 GeneticVariation group GWASCAT Genome-wide association study identifies novel genetic variants contributing to variation in blood metabolite levels. 26068415 2015
CUI: C0201874
Disease: Amino acids measurement
Amino acids measurement 		0.100 GeneticVariation group GWASCAT Genome-wide study for circulating metabolites identifies 62 loci and reveals novel systemic effects of LPA. 27005778 2016
CUI: C0202202
Disease: Protein measurement
Protein measurement 		0.100 GeneticVariation group GWASCAT Genome-wide study for circulating metabolites identifies 62 loci and reveals novel systemic effects of LPA. 27005778 2016
CUI: C0015190
Disease: Euthyroid Sick Syndromes
Euthyroid Sick Syndromes 		0.010 Biomarker disease BEFREE Herein, we aimed to evaluate the central and peripheral expression of genes involved in the transport (MCT8/<i>Slc16a2</i> and MCT10/<i>Slc16a10</i>), metabolism (<i>Dio1, Dio2</i>, and <i>Dio3</i>) and action (<i>Thra</i> and <i>Thrb</i>) of TH during NTIS induced by fasting or sepsis. 29118715 2017
CUI: C0086543
Disease: Cataract
Cataract 		0.010 Biomarker disease BEFREE Interestingly, the absence of LAT2 led to increased incidence of cataract in mice, in particular in older females, and a synergistic effect was observed with simultaneous lack of TAT1. 31231240 2019
CUI: C0014772
Disease: Red Blood Cell Count measurement
Red Blood Cell Count measurement 		0.100 GeneticVariation phenotype GWASCAT Leveraging Polygenic Functional Enrichment to Improve GWAS Power. 30595370 2019
CUI: C0427460
Disease: Red cell distribution width determination
Red cell distribution width determination 		0.100 GeneticVariation phenotype GWASCAT Leveraging Polygenic Functional Enrichment to Improve GWAS Power. 30595370 2019